Experienced in Myelofibrosis

Dr. Irene Dy

Hematology
MultiCare Deaconess Medical Office Building 1
910 W 5th Ave, 
Spokane, WA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Myelofibrosis
MultiCare Deaconess Medical Office Building 1
910 W 5th Ave, 
Spokane, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Irene Dy is a Hematologist in Spokane, Washington. Dr. Dy is rated as an Experienced provider by MediFind in the treatment of Myelofibrosis. Her top areas of expertise are Myelodysplastic Syndrome (MDS), Thrombocytopenia, Lung Cancer, and Paget Disease of the Breast.

Her clinical research consists of co-authoring 6 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Licenses
Internal Medicine in CA
Hospital Affiliations
Deaconess Medical Center
Prosser Memorial Hospital
Kadlec Regional Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Coordinated Care
  • HMO
  • MANAGED MEDICAID PLAN
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Premera
  • EPO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

MultiCare Deaconess Medical Office Building 1
910 W 5th Ave, Spokane, WA 99204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
Enrollment Status: Completed
Publish Date: July 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab
Study Phase: Phase 2
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2025
Intervention Type: Other
Study Phase: Phase 3
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
Enrollment Status: Completed
Publish Date: September 03, 2024
Intervention Type: Drug, Biological
Study Drugs: Docetaxel, Gemcitabine, Gemcitabine Hydrochloride, Pembrolizumab, Pemetrexed, Pemetrexed Disodium, Ramucirumab
Study Phase: Phase 2
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Enrollment Status: Terminated
Publish Date: July 27, 2022
Intervention Type: Drug, Other
Study Drug: Varenicline
Study Phase: Phase 3
View 5 Less Clinical Trials

6 Total Publications

Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 07, 2022
Similar Doctors
Experienced in Myelofibrosis
Dr. Hakan Kaya
Hematology
Experienced in Myelofibrosis
Dr. Hakan Kaya
Hematology
601 South Sherman Street, 
Spokane, WA 
 (132.4 miles away)
509-228-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hakan Kaya is a Hematologist in Spokane, Washington. Dr. Kaya is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Large-Cell Immunoblastic Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Kaya is currently accepting new patients.

Experienced in Myelofibrosis
Dr. Kevin P. Mulvey
Hematology Oncology | Oncology | Hematology
Experienced in Myelofibrosis
Dr. Kevin P. Mulvey
Hematology Oncology | Oncology | Hematology

Kootenai Health Inc

1440 E Mullan Ave, 
Post Falls, ID 
 (149.9 miles away)
208-625-4900
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Kevin Mulvey is a Hematologist Oncology specialist and an Oncologist in Post Falls, Idaho. Dr. Mulvey is rated as a Distinguished provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Follicular Lymphoma, Large-Cell Immunoblastic Lymphoma, Richter Syndrome, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration. Dr. Mulvey is currently accepting new patients.

Experienced in Myelofibrosis
Dr. Maury N. Blitman
Hematology Oncology | Hematology | Oncology
Experienced in Myelofibrosis
Dr. Maury N. Blitman
Hematology Oncology | Hematology | Oncology

Cancer Care Northwest Centers P S

1204 N Vercler Rd, 
Spokane, WA 
 (137.6 miles away)
509-228-1000
Languages Spoken:
English, Hindi, Mandarin, Spanish, Urdu
See accepted insurances
Accepting New Patients
Offers Telehealth

Maury Blitman is a Hematologist Oncology specialist and a Hematologist in Spokane, Washington. Dr. Blitman is rated as an Advanced provider by MediFind in the treatment of Myelofibrosis. His top areas of expertise are Pleuropulmonary Blastoma, Clear Cell Sarcoma, Chromophobe Renal Cell Carcinoma, and WT1-Related Wilms Tumor Syndromes. Dr. Blitman is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dy's expertise for a condition
ConditionClose
      View All 23 Advanced Conditions
      View All 116 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile